Maverix Cryo Biopsy Pro (MCB Pro) (MCBP-1000); Maverix Cryo Cartridge (CC-1000)
Serpex Medical · Decision date Sep 2, 2026
What did the FDA decide?
Serpex Medical received a substantially equivalent (SESE) decision for K262420 on September 2, 2026, covering the Maverix Cryo Biopsy Pro (MCB Pro) probe (MCBP-1000) and the Maverix Cryo Cartridge (CC-1000). The submission was received July 16, 2026, and reviewed under 21 CFR 878.4350 as a Class II cryosurgical unit and accessory, product code GEH, in the General and Plastic Surgery panel. A SESE decision is a 510(k) clearance, not a PMA approval.
The system pairs a sterile, single-use flexible cryoprobe with a non-sterile, single-use nitrous oxide cartridge; the cartridge is loaded by a non-sterile assistant and suspended outside the sterile field while the probe's distal end stays within it. The summary names the ERBECRYO 2 cryosurgical unit and Erbe flexible cryoprobes (K190651, cleared January 7, 2020) as predicate, with differences in refrigerant gas, gas delivery, sheath-adjustable working length and a pointed, sheathed tip. The source does not include performance testing results or the full indications comparison.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262420
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Serpex Medical
- Product code
- GEH
- Decision code
- SESE
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Unit, Cryosurgical, Accessories.
- Applicant
- Serpex Medical
- Product code
- GEH
- FDA device class
- 2
FDA decision timeline
K262420 received
Application receipt date recorded by FDA.
K262420 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code GEH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cryoconcepts LP | 510(k) clearance | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Serpex Medical
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Santa Clara, CA
Sources and methodology
- Original FDA record: K262420
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records